Find the latest episode of "The Uncertain Hour" here. Listen

Second opinion: Bad news for Glaxo

Stephen Beard Jul 18, 2007
HTML EMBED:
COPY

Second opinion: Bad news for Glaxo

Stephen Beard Jul 18, 2007
HTML EMBED:
COPY

TEXT OF STORY

Doug Krizner: GlaxoSmithKline’s second-biggest selling drug, Avandia, is in trouble again. German researchers say the diabetes medication doesn’t work, and it could even be harmful. Stephen Beard reports.


Stephen Beard: The German research is pretty damning.

Dr. Bernd Richter of Heinrich Heine University in Dusseldorf found no evidence that Avandia brought any benefit to diabetes patients.

On the other hand, he said, there was plenty of evidence of negative side effects, including weight gain and bone fractures and, more worryingly, an increased risk of heart attack.

Dr. Bernd Richter: We found what is called oedema, that is swelling in the ankles and the lower limbs which could be the first step towards heart failure, was approximately doubled.

His findings are a fresh embarrassment for Glaxo.

A U.S. researcher came to similar conclusions about Avandia earlier in May. Analysts then slashed their earnings forecasts and the Glaxo share price slumped. A Glaxo spokesman dismissed the German findings as inconclusive.

In London, this is Stephen Beard for Marketplace.

Marketplace is on a mission.

We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.

Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?

Your donation is critical to the future of public service journalism. Support our work today – for as little as $5 – and help us keep making people smarter.